Jiangsu Simcere Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., explained in plain language.
A pharmaceutical company developing drugs, subsidiary of Simcere.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to test how common drugs interact with experimental medicine Results expected Oct 2026 (estimated)
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Stopped earlyThis early-stage trial is testing an experimental drug called SIM0348, given alone or with another drug (sintilimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the safety and tolerability of the drug, how it m…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New cancer drug tested in 13 patients – early trial ends
Disease control Stopped earlyThis early-stage trial tested a new drug called SIM0501, alone or with another drug (olaparib), in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body. The study was s…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC